Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects

Summary

This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and digoxin (Lanoxin®) 0.125 mg QD, a sensitive P-gp substrate recommended by FDA.

Timeline

Start

2009-02

Primary completion

2009-05

Completion

2009-05

Drugs

Indications